Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Author(s):
Anink, J.; Otten, M.H.; Gorter, S.L.; Prince, F.H.M.; Rossum, M.A.J. van; Berg, J.M. van den; Pelt, P.A. van; Kamphuis, S.; Brinkman, D.M.C.; Swen, W.A.A.; Swart, J.F.; Wulffraat, N.M.; Dolman, K.M.; Koopman-Keemink, Y.; Hoppenreijs, E.P.A.H.; Armbrust, W.; Cate, R. ten; Suijlekom-Smit, L.W.A. van
Published
2013
Publication type
Article / Letter to editor
juvenile idiopathic arthritisTNF-alpha inhibitorsqualitative researchdecision making
Date issued
2013-09-30
Language
English
Is part of
Rheumatology (2013), Vol. 52, no. 9, p. 1674-1679
hdl
1887/100400
doi
10.1093/rheumatology/ket170